Back to top
more

Celsion Corporation (CLSN)

(Delayed Data from NSDQ)

$2.18 USD

2.18
85,165

0.00 (-0.03%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.18 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Arena Pharmaceuticals' (ARNA) Loss Widens in Q1 But Stock Up

by Zacks Equity Research

Arena Pharmaceuticals (ARNA) reports loss in the first quarter of 2019 on an adjusted basis. Revenues of $801.1 million include upfront payment of $800 million from United Therapeutics.

Will Celsion (CLSN) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Celsion (CLSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Celsion (CLSN) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Celsion (CLSN) closed at $2.19, marking a -1.79% move from the previous day.

Celsion (CLSN) Flat As Market Sinks: What You Should Know

by Zacks Equity Research

Celsion (CLSN) closed at $2.20 in the latest trading session, marking no change from the prior day.

Medicines Company (MDCO) Q1 Loss Narrows, Inclisiran in Focus

by Zacks Equity Research

The Medicines Company (MDCO) suffers narrower-than-expected loss in Q1. The company progresses well with its sole pipeline candidate, inclisiran.

AstraZeneca's (AZN) Q1 Earnings Beat, New Drugs Drive Sales

by Zacks Equity Research

AstraZeneca (AZN) beats earnings and sales estimates in the first quarter. New drugs, especially cancer drugs, drive revenues.

Is Celsion (CLSN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (CLSN) Outperforming Other Medical Stocks This Year?

Alexion (ALXN) Q1 Earnings Beat Estimates, Guidance Raised

by Zacks Equity Research

Alexion (ALXN) beats earnings and sales estimates in the first quarter of 2019 and raises guidance for the year.

Ultragenyx's (RARE) UX007 Gets Fast Track Status by FDA

by Zacks Equity Research

Ultragenyx???s (RARE) UX007 receives Fast Track designation and Rare Pediatric Disease designation by the FDA for the treatment of long-chain fatty acid oxidation disorders.

ProQR Initiates Dosing in Phase II/III Eye Disorder Study

by Zacks Equity Research

ProQR Therapeutics (PRQR) initiates dosing in the phase II/III study on sepofarsen, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.

Celsion (CLSN) Moves to Strong Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Celsion (CLSN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks.com highlights: Rosehill Resources, Navios Maritime Partners, AMC Entertainment Holdings, Entercom Communications and Celsion

by Zacks Equity Research

Zacks.com highlights: Rosehill Resources, Navios Maritime Partners, AMC Entertainment Holdings, Entercom Communications and Celsion

    Swarup Gupta headshot

    5 Cheap Breakout Stocks for Formidable Returns

    by Swarup Gupta

    The technique seeks to identify stocks whose prices are fluctuating within a specific band.

      Celsion (CLSN) Shares March Higher, Can It Continue?

      by Zacks Equity Research

      As of late, it has definitely been a great time to be an investor in Celsion Corporation (CLSN)

        Ekta Bagri headshot

        4 Biotech Stocks to Bet on in the Second Half of 2018

        by Ekta Bagri

        While the first half did not turn out to be great for the biotech sector, the second half is expected to be much better. Here, we list four biotechs poised for a good run.

          Celsion's Phase I/II Cancer Study Initiation Gets FDA Nod

          by Zacks Equity Research

          Celsion's (CLSN) plan for phase I/II study to evaluate DNA-based immunotherapy, GEN-1, in ovarian cancer gets FDA approval and clearance for initiation.

            Zacks.com highlights: Hecla Mining, Cloud Peak Energy, Celsion, QuickLogic and Precision Drilling

            by Zacks Equity Research

            Zacks.com highlights: Hecla Mining, Cloud Peak Energy, Celsion, QuickLogic and Precision Drilling

              Swarup Gupta headshot

              5 Breakout Stocks Offering Terrific Returns

              by Swarup Gupta

              If properly implemented, such a strategy could deliver impressive returns.

                Cancer Space Last Week Update: Pipeline Expansion in Focus

                by Zacks Equity Research

                Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.

                  Celsion's Immunotherapy Candidate Impresses, Stock Surges

                  by Zacks Equity Research

                  Celsion's (CLSN) pipeline candidate, GEN1, controls ovarian cancer in all patients in the phase Ib study and achieves a historical improvement in progression free survival.

                    Stocks Near 52-Week Lows: 4 Attractive Picks

                    by Zacks Equity Research

                    Fundamentally strong stocks trading around their 52-week lows make for a great bargain, despite how weak the broader market considers them right now.

                      Celsion Completes Ovarian Cancer Trial Enrollment, Stock Up

                      by Zacks Equity Research

                      Celsion Corp. (CLSN) shares rose after the company has announced completion of enrolment in a phase Ib study, evaluating its immunotherapy, GEN-1 in combination with neoadjuvant chemotherapy for treatment of advanced ovarian cancer.

                        Achillion (ACHN) Reports Wider-than-Expected Loss in Q1

                        by Zacks Equity Research

                        Achillion Pharmaceuticals, Inc. (ACHN) reported a loss of 15 cents per share in the first quarter, wider than the Zacks Consensus Estimate of a loss of 8 cents. In the year-ago quarter, the company had reported a loss of 13 cents per share.

                          Forget Gilead, Buy These Small-Cap Biotech Stocks Instead

                          by Zacks Equity Research

                          At this juncture, we advise investors to forget Gilead (GILD), a Zacks Rank #4 (Sell) stock, and invest in some other small cap biotech stocks (market capitalization below $200 million) that carry an impressive Zacks Rank.